David Hsieh, M.D.
Department Internal Medicine
You have reached the Academic Profile.
For more information on the doctor and patient care, please visit the clinical profile.View Clinical Profile
David Hsieh, M.D., is an Assistant Professor in the Department of Internal Medicine at UT Southwestern Medical Center and a member of its Division of Hematology and Oncology.
Originally from Tucson, Arizona, Dr. Hsieh earned his medical degree at the University of Arizona College of Medicine. He completed internal medicine residency training at Mount Auburn Hospital in Cambridge, Massachusetts. He then completed advanced training through a fellowship in hematology and oncology at UT Southwestern Medical Center.
Board-certified in internal medicine and medical oncology, Dr. Hsieh joined the UT Southwestern faculty in 2019.
Dr. Hsieh leads clinical trials testing new drugs for liver cancers including hepatocellular carcinoma and cholangiocarcinomas. His other research interests include translational studies to understand mechanisms behind the variable effectiveness of cancer therapies between patients and the development of treatment biomarkers. He also researches processes, policies, and biases in scientific research and medicine.
Dr. Hsieh's clinical interests include hepatocellular carcinoma and biliary tract cancers including cholangiocarcinomas and gall bladder cancers.
His awards and honors include an Early Career Investigator Award from the Cancer Prevention and Research Institute of Texas.
- Hepatocellular carcinoma
- Liver cancer
- Mechanisms of drug resistance
- Predictive biomarkers
- Genetic features and therapeutic relevance of emergent circulating tumor DNA alterations in refractory non-colorectal gastrointestinal cancers.
- Hsiehchen D, Bucheit L, Yang D, Beg MS, Lim M, Lee SS, Kasi PM, Kaseb AO, Zhu H, Nat Commun 2022 Dec 13 1 7477
- Clonal hematopoiesis and differential outcomes after immune checkpoint blockade.
- Hsiehchen D, Sfreddo HJ, Zhao K, Han CY, Morris LGT, Cancer Cell 2022 Oct 40 10 1071-1072
- Adherence to a Federal Hospital Price Transparency Rule and Associated Financial and Marketplace Factors.
- Haque W, Ahmadzada M, Janumpally S, Haque E, Allahrakha H, Desai S, Hsiehchen D, JAMA 2022 06 327 21 2143-2145
- Impact of tumor mutational burden on checkpoint inhibitor drug eligibility and outcomes across racial groups.
- Hsiehchen D, Espinoza M, Valero C, Ahn C, Morris LGT, J Immunother Cancer 2021 11 9 11
- DNA Repair Gene Mutations as Predictors of Immune Checkpoint Inhibitor Response beyond Tumor Mutation Burden.
- Hsiehchen D, Hsieh A, Samstein RM, Lu T, Beg MS, Gerber DE, Wang T, Morris LGT, Zhu H, Cell Rep Med 2020 Jun 1 3
- Nearing saturation of cancer driver gene discovery.
- Hsiehchen D, Hsieh A, J Hum Genet 2018 Sep 63 9 941-943
- Multinational teams and diseconomies of scale in collaborative research.
- Hsiehchen D, Espinoza M, Hsieh A, Sci Adv 2015 Sep 1 8 e1500211